A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer

Trial Profile

A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Biliary cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 13 Sep 2017 Results presented in a 4SC media release.
    • 13 Sep 2017 Results published in the Media Release
    • 13 Sep 2017 According to a 4SC media release, results of this trial (n=27) were presented at the ESMO 2017 Congress by Yakult Honsha.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top